You are currently viewing Immunotherapy in Triple Negative Breast Cancer (TNBC)
Immunotherapy in Triple Negative Breast Cancer (TNBC)

Immunotherapy in Triple Negative Breast Cancer (TNBC)

Immunotherapy in Triple-Negative Breast Cancer (TNBC) Is implemented. It accounts for about 13% of breast cancer cases and is named because it tests negative for estrogen and progesterone receptors and for the HER2 protein. Triple-negative cancers tend to grow faster and often carry a worse prognosis

Triple-negative breast cancer (TNBC) is an aggressive subset with its immune activated in tumor microenvironment, suggesting that immunotherapy may be a viable treatment strategy.

Phase III clinical trials (CT): reveal that atezolizumab or pembrolizumab is well-tolerated in combination with chemotherapy, with progression-free survival benefit in metastatic programmed death ligand-1 (PD-L1)-positive TNBC patients who are treated with it as first-line therapy. 

CT- IMpassion130, -a combination of atezolizumab and nab-paclitaxel is now considered a standard of care for the treatment of PD-L1-positive advanced TNBC

Early TNBC:  pembrolizumab and atezolizumab are tested in combination with standard neoadjuvant chemotherapy, resulting in a higher complete pathologic response rate. 

These findings are proof of principle for immunotherapy in both early and advanced Triple Negative Breast Cancer.

Adding immunotherapy with a chemotherapy regimen can improve the likelihood that early-stage triple-negative breast cancer as per data from a clinical trial led by Dana-Farber/Brigham.  

Future directions include studies, whether chemotherapy-checkpoint inhibitor combinations are going to be effective in other types of breast cancer

Also Read:

Which cancers are treated with immunotherapy? Types of immunotherapy used to treat cancer.

About Breast Cancer and Its Various Stages

Dr Sajjan Rajpurohit

Best cancer specialist in Delhi, Dr. Sajjan Rajpurohit has been a practicing physician for the past 22 years and is currently working as Director in the Medical Oncology at BLK-Max Super Speciality Hospital, New Delhi. He is also a European certified as Best Medical Oncologist in Delhi, India, ESMO, Geneva. Dr. Sajjan Rajpurohit is acknowledged as a versatile veteran in treating various types of cancers. A qualified MBBS with MD in Medicine and DNB in Medical Oncology.